{"id":"W4403213466","doi":"10.1016/j.euo.2024.09.013","title":"Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Olaparib; Asymptomatic; Placebo; Internal medicine; Oncology; Urology; Cancer; Androgen deprivation therapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002646749,0.001098934,0.002537981,0.0004002442,0.0002680161,0.001175778,0.000690944,0.0008361246,0.003027036],"category_scores_gemma":[0.002433444,0.000370331,0.003315385,0.0004065603,0.000670602,0.0006418062,0.0003840053,0.002167033,0.0004688236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007491444,"about_ca_system_score_gemma":0.0009909931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005045735,"about_ca_topic_score_gemma":0.001734336,"domain_scores_codex":[0.9987878,0.0007686114,0.0001020385,0.0001229282,0.0001084683,0.0001101236],"domain_scores_gemma":[0.9983659,0.0005461283,0.0005454199,0.00009507222,0.00008182531,0.0003654888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9701205,0.001813356,0.002206684,0.000536733,0.00242823,0.00004033009,0.00005474112,0.0004077198,0.002386773,0.00003820107,0.0004163746,0.0195503],"study_design_scores_gemma":[0.8008533,0.1739525,0.01651156,0.000121466,0.004739394,0.0002037895,0.00006943456,0.0007597297,0.001277106,0.0003284995,0.001142294,0.00004097182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827435,0.01318872,0.0003228117,0.0004809095,0.000200789,0.0008533517,0.0009841225,0.00005521251,0.001170616],"genre_scores_gemma":[0.9948376,0.002365618,0.0003772836,0.0003198189,0.0002125607,0.0005344474,0.0007794391,0.000008678081,0.0005644817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003027036,"threshold_uncertainty_score":0.0139975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06115839959823703,"score_gpt":0.3709653573860134,"score_spread":0.3098069577877763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}